Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is among the most frequently occurring cancers and the leading causes of cancer mortality worldwide. Identification of the signaling pathways regulating liver carcinogenesis is critical for developing novel chemoprevention and targeted therapies. C-Jun N-terminal kinase (JNK) is a member of a larger group of serine/threonine (Ser/Thr) protein kinases known as the mitogen-activated protein kinase (MAPK) family. JNK is an important signaling component that converts external stimuli into a wide range of cellular responses, including cell proliferation, differentiation, survival, migration, invasion, and apoptosis, as well as the development of inflammation, fibrosis, cancer growth, and metabolic diseases. Because of the essential roles of JNK in these cellular functions, deregulated JNK is often found to contribute to the development of HCC. Recently, the functions and molecular mechanisms of JNK in HCC development have been addressed using mouse models and human HCC cell lines. Furthermore, recent studies demonstrate that the activation of JNK by oncogenes can promote the development of cancers by regulating the transforming growth factor (TGF)-β/Smad pathway, which makes the oncogenes/JNK/Smad signaling pathway an attractive target for cancer therapy. Additionally, JNK-targeted therapy has a broad potential for clinical applications. In summary, we are convinced that promising new avenues for the treatment of HCC by targeting JNK are on the horizon, which will undoubtedly lead to better, more effective, and faster therapies in the years to come.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 7×
“NAFLD is strongly associated with an increased level of serum free fatty acids (FFAs), and report shows that the FFAs levels are increased in patients with NASH and correlate with disease severity [96].”
BackgroundInfluentialJNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis
Lei, K., & Davis, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438011100 · Cited by 1,068
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., & Karin, M. (1991) · Nature · doi:10.1038/354494a0 · Cited by 789
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
Owens, D. M., & Keyse, S. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210412 · Cited by 777 · cited 1×
“Moreover, the kinase activity of JNKs is regulated by interaction with scaffold proteins [11], as well as dual-specificity phosphatases [12] and nuclear factor-kB (NF-kB) transcription factors [13].”
BackgroundTargeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585 · cited 1×
“c-Fos induced osteosarcomas and skin tumors induced by chronic activation of the Ras pathway were reduced in JunAA mice [22].”
BackgroundKim, B.-J., Ryu, S.-W., & Song, B.-J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510644200 · Cited by 470
JNK1 but not JNK2 promotes the development of steatohepatitis in mice
Schattenberg, J. M., Singh, R., Wang, Y., Lefkowitch, J. H., Rigoli, R. M., Scherer, P. E., & Czaja, M. J. (2006) · Hepatology · doi:10.1002/hep.20999 · Cited by 384 · cited 1×
“In addition, both JNK1 and JNK2 have been implicated in insulin resistance, although JNK1 is more strongly associated with steatohepatitis [103, 104].”
BackgroundPlasma total and free fatty acids composition in human non-alcoholic steatohepatitis
TAVARES DE ALMEIDA, I., CORTEZ-PINTO, H., FIDALGO, G., RODRIGUES, D., & CAMILO, M. E. (2002) · Clinical Nutrition · doi:10.1054/clnu.2001.0529 · Cited by 243
Requirement of the JIP1 scaffold protein for stress-induced JNK activation
Whitmarsh, A. J., Kuan, C.-Y., Kennedy, N. J., Kelkar, N., Haydar, T. F., Mordes, J. P., Appel, M., Rossini, A. A., Jones, S. N., Flavell, R. A., et al. (2001) · Genes & Development · doi:10.1101/gad.922801 · Cited by 238 · cited 1×
“Moreover, the kinase activity of JNKs is regulated by interaction with scaffold proteins [11], as well as dual-specificity phosphatases [12] and nuclear factor-kB (NF-kB) transcription factors [13].”
BackgroundIdentification of a new JNK inhibitor targeting the JNK-JIP interaction site
Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, L.-H., Cellitti, J. F., Riel-Mehan, M., Emdadi, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805677105 · Cited by 186
A Peptide Inhibitor of c-Jun N-Terminal Kinase for the Treatment of Endotoxin-Induced Uveitis
Touchard, E., Omri, S., Naud, M.-C., Berdugo, M., Deloche, C., Abadie, C., Jonet, L., Jeanny, J.-C., Crisanti, P., de Kozak, Y., et al. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4733 · Cited by 43
Beydoun, T., Deloche, C., Perino, J., Kirwan, B.-A., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0247 · Cited by 39
El Zaoui, I., Touchard, E., Berdugo, M., Abadie, C., Kowalczuk, L., Deloche, C., Zhao, M., Naud, M.-C., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0019 · Cited by 31
Cited by
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322
“The JNK‐induced Bcl‐2 pathway is responsible for the protective role of autophagy in HCC.104,105 The dual roles of JNK1‐mediated Bcl‐2 phosphorylation in autophagy are dictated by time‐dependent processes.106,107 Rapid Bcl‐2 phosphorylation occurs initially to promote cell survival via disrupting the Bcl‐2‐beclin 1 co…”
BackgroundInfluentialSeo, W., Gao, Y., He, Y., Sun, J., Xu, H., Feng, D., Park, S. H., Cho, Y.-E., Guillot, A., Ren, T., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.018 · Cited by 218
Self-citationRole of JNK signaling in oral cancer: A mini review
Gkouveris, I., & Nikitakis, N. G. (2017) · Tumor Biology · doi:10.1177/1010428317711659 · Cited by 87
Fang, S., Wu, Y., Zhang, H., Zeng, Q., Wang, P., Zhang, L., Yan, G., Zhang, G., & Wang, X. (2022) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2022.102907 · Cited by 10
Metadata
- Authors
- Wang, J., & Tai, G.
- Venue
- Targeted Oncology
- Published
- 2016-07-08
- Volume
- 11
- Issue
- 6
- Pages
- 723-738
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- OpenAlex
- W2472672348
- Cited by
- 45
- References
- 15
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.